Loading…
NZ/Australian biotech that developed trofinetide (marketed as Daybue by US partner Acadia) for Rett syndrome and related neurodevelopmental disorders.
NZ/Australian biotech that developed trofinetide (marketed as Daybue by US partner Acadia) for Rett syndrome and related neurodevelopmental disorders.
Owns the drug but does not sell it: Acadia handles sales in North America and pays Neuren a royalty on them plus milestone payments, so income depends on Daybue sales. Neuren spends part of that cash developing its follow-on drug NNZ-2591 in other rare neurological disorders.
In one line: A royalty-earning CNS biotech partnered with Acadia Pharmaceuticals.
Moat: narrow (IP / patents). Patent-protected drug licensed to a US commercial partner generates royalty/milestone income.
Headquarters: Auckland, New Zealand · Founded: 2003
Size Neuren Pharmaceuticals (NEU.AX) is an Australia Health Care company (Pharmaceuticals: Generic) with a market value of $2.04B, the 117th largest of 316 Australia companies the cockpit tracks. Shares closed at A$23.24 on 6 Nov 2026.
Performance Over six months the shares gained 82.8%, against -11.3% for the median peer and +4.1% for the Australia market (cap-weighted) — highest of 6 in its peer set.
Growth Revenue fell 68.0% over the last twelve months (peer median +2.5%); the operating margin is 19.9% (peer median -34.0%).
Valuation It trades at 39.5× forward earnings.
Capital Return on invested capital runs 5.7 points above its cost of capital (15.0% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | A$69.5M | A$64.6M | A$213M | A$232M | A$14.6M |
| Revenue growth | — | -70% | -8% | +1,494% | — |
| Gross profit | A$69.5M | A$64.6M | A$213M | n/a | A$14.5M |
| EBITDA | A$13.9M | A$22.0M | A$176M | A$199M | -A$1.59M |
| Net income | A$20.3M | A$30.4M | A$142M | A$157M | A$184,000 |
| Free cash flow | A$5.08M | A$125M | -A$11.3M | A$185M | A$3.58M |
| Capital expenditure | A$40,000 | A$37,000 | A$10,000 | A$40,000 | A$19,000 |
| Total debt | n/a | A$0 | A$0 | A$0 | A$0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Neuren Pharmaceuticals NEU.AX | $2.04B | +83% | -68% | 20% | 39.5× | n/a |
| ACADIA Pharmaceuticals ACAD | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% |
| Anavex Life Sciences AVXL | n/a | -64% | n/a | n/a | n/a | n/a |
| Ovid Therapeutics OVID | $557M | +2% | -76% | -3,687% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEU.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.7% | -16.0% | highest of 6 |
| 6-month return | +82.8% | -11.3% | highest of 6 |
| Distance from 52-week high | -2.8% | -48.7% | highest of 6 |
| Revenue growth (TTM) | -68.0% | +2.5% | lowest of 6 |
| Operating margin | 19.9% | -34.0% | highest of 6 |
| Forward P/E | 39.5× | n/a | — |
| ROIC minus cost of capital | +5.7 pp | -11.2 pp | highest of 6 |
| Net debt / EBITDA | -20.6× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Neuren Pharmaceuticals NEU.AX | Australia | $2.04B | +83% | -68% | 20% | 39.5× | n/a | n/a |
| Vigonvita Life Sciences 2630.HK | Hong Kong | $1.48B | -11% | +763% | -327% | n/a | n/a | n/a |
| Suzhou Ribo Life Science 6938.HK | Hong Kong | $939M | -29% | +4% | -187% | n/a | n/a | n/a |
| Hikma Pharmaceuticals HIK.L | United Kingdom | $4.59B | +18% | +2% | 20% | 9.9× | 1.4% | +6.8% |
| Realcan Pharmaceutical 002589.SZ | China | $628M | -11% | -4% | 0% | n/a | 17.7% | -23.1% |
| Tibet Duo Rui Pharmaceutical 301075.SZ | China | $552M | -45% | -6% | -34% | n/a | n/a | n/a |